论文部分内容阅读
卵泡刺激素受体(follicle stimulating hormone receptor,FSHR)是一种G蛋白偶联受体,仅在哺乳动物生殖系统中痕量表达。新近研究发现,FSHR在多种肿瘤(如前列腺癌、乳腺癌、肝癌和肾癌等)的血管内皮上高度表达,并在疾病的发展进程中发挥重要作用。因此,FSHR是肿瘤诊治的一个潜在的靶点。开发FSHR靶向药物将有利于肿瘤的诊断、靶向治疗及个体化方案的选择和预后的判定。本文就FSHR及其特异性配体的研究进展作一综述。
Follicle stimulating hormone receptor (FSHR) is a G-protein coupled receptor that is only expressed in the mammalian reproductive system. Recent studies have found that FSHR is highly expressed on the vascular endothelium of many kinds of tumors such as prostate cancer, breast cancer, liver cancer and kidney cancer, and plays an important role in the progression of the disease. Therefore, FSHR is a potential target for diagnosis and treatment of cancer. The development of FSHR-targeted drugs will facilitate the diagnosis of tumors, targeted therapies and the selection of individualized programs and the prognosis. This review summarizes the research progress of FSHR and its specific ligands.